Abstract-There are strong data favoring the pathogenic role of angiotensin II type 1 receptor (AT 1 ) activation with subsequent promotion of myocyte growth and cardiac fibrosis in the development of cardiac hypertrophy and heart failure. An emerging hypothesis suggests that the activity of the angiotensin II type 2 receptor (AT 2 ) may counterregulate AT 1 receptor effects during cardiac development and during the evolution of cardiac hypertrophy and heart failure. In this review, we examine the potential role of AT 2 activity in the context of this hypothesis. In contrast to the counterregulatory hypothesis, studies in mice with an overabundance of, or a deficiency in, the AT 2 receptor do not suggest that AT 2 signaling is essential for cardiac development. Moreover, the proposed antigrowth effects of AT 2 receptor signaling in pathological cardiac hypertrophy could not be shown in two mice models both deficient in AT 2 receptors. The role of AT 2 receptor signaling in cardiac fibrosis is, however, still debatable because of conflicting data in the same two studies. In angiotensin II-evoked apoptosis in cardiomyocytes, the proposed proapoptotic role of AT 2 activity could not be confirmed. Furthermore, in the progression from the bench to bedside, the results of two large clinical trials in heart failure, namely ELITE II and Val-HeFT, can be explained without ascribing a major protective role to the unopposed activity of the AT 2 receptor in the failing myocardium. In this review, we conclude that the collective evidence does not strongly support a net beneficial effect of AT 2 stimulation in the diseased myocardium.
T wo of the most powerful cardiovascular regulators are the ␤-adrenergic and the renin-angiotensin system (RAS). The strength of the two systems is such that, between them, they virtually control cardiovascular physiology. The ␤-adrenergic system is concerned with the fight-or-flight reactions, achieving abrupt increases in heart rate and cardiac output, whereas in adult life, the RAS controls blood volume, peripheral vascular tone, and hence the blood pressure (Table  1) . Both systems are subject to counterregulatory balances, postulated to be overridden by sustained activation in heart failure. Overactivity of the ␤-adrenergic system is selflimited by the uncoupling, internalization, and inactivation of the ␤-adrenergic receptor. In contrast, the mechanism of autoregulation of angiotensin stimulation in heart failure is less well-defined (Table 1) . Recent reviews suggest that activity of the angiotensin II type 2 receptor (AT 2 ) may counterbalance the putative detrimental effects of angiotensin II type 1 receptor (AT 1 ) activation in heart failure via mediating opposite cellular functions. 1, 2 To explore the putative counterregulatory role of AT 2 receptor signaling, we need to define the role of AT 1 signaling in the heart. It is already known that AT 1 stimulation leads to vasoconstriction, cell growth, positive inotropy, catecholamine release, and increased aldosterone secretion with fibrosis, all deemed to have a detrimental component in cardiac hypertrophy and heart failure. Thus, to confer counterregulatory effects, AT 2 receptor stimulation should oppose one or more of the phenotypic effects of AT 1 receptor stimulation. In this review, we examine the putative individual components of AT 2 receptor signaling in the heart, ie, in cardiac growth, apoptosis, and fibrosis. We also discuss the results of recent clinical trials aimed at specific inhibition of the RAS in heart failure. We conclude that these proposed counterregulatory effects may not be of major significance in the overall regulation of the RAS in cardiac hypertrophy and heart failure.
Signaling Pathways
Before describing the phenotypic response to the modulation of the AT 2 receptor system in the myocardium, we will briefly review AT 1 and AT 2 receptor subtype signaling. These data regarding signal transduction could provide insight into the counterregulatory hypothesis. In response to mechanical stretch of neonatal cardiomyocytes, both AT 1 and AT 2 receptors are upregulated. 3 AT 1 receptor activates several welldefined paths, including vascular contraction mediated by inositol triphosphate (IP 3 ) and release of calcium from the sarcoplasmic reticulum, whereas myocardial growth is mediated by protein kinase C (PKC) activity and a multiplicity of paths that lead to mitogen-activated protein (MAP) kinase activity. Furthermore, through a path that involves oxygen radicals and ceramide, nuclear factor (NF)-B may be activated. 4 The latter is a pleiotropic nuclear regulatory peptide promoting both beneficial and adverse effects. 5 Some pathways linked to stimulation of the AT 2 receptors are similar to AT 1 effects. 6 NF-B activation may be involved, especially in vascular smooth muscle, which in turn could lead to growth, fibrosis, or apoptosis, in a context-dependent manner. 4 The AT 2 receptor may exert adverse effects during ischemia/ reperfusion, mediated by IP 3 and PKC⑀. 7 There may also be a myocardial kinin protective path involving nitric oxide, bradykinin, and prostaglandins. 2, 8 A similar vascular kinin protective path is found in transgenic mice overexpressing the AT 2 receptor. 9 However, once bradykinin is formed, it might inhibit the formation of angiotensin II 10 to limit the proposed beneficial counterregulatory effects.
AT 2 Receptor in Cardiac Growth
In vascular smooth muscle cells, the AT 2 receptor exerts an antiproliferative effect whereas the AT 1 receptor promotes growth. 2 In a variety of models of myocardial growth, both AT 1 and AT 2 receptors are upregulated. 3, 11, 12 In neonatal rat cardiomyocytes, the antagonism of AT 2 receptor signaling in response to a hypertrophic stimulus suggests that the AT 2 receptor does mediate an antigrowth effect, 13 as supported by an acute study of angiotensin-induced hypertrophic growth in rats. 14 In contrast, when left ventricular hypertrophy (LVH) was induced by chronic infusion of angiotensin II in rats, losartan inhibited this process, showing the role of AT 1 receptors, whereas AT 2 receptor block neither changed the blood pressure nor the degree of ventricular hypertrophy. 15 Finally, if the AT 2 receptor has antigrowth effects, then its deletion by genetic ablation should lead to LVH in response to a pressure load. Two recent studies using independently generated AT 2 receptor-null mice dispute this hypothesis (Table 2 ). In the first study, targeted deletion of the AT 2 receptor prevented LVH in response to aortic banding, and 
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contractile function remained normal. 16 In the second study, the heart-to-body weight ratio increased by Ϸ15% in both deletion and wild-type mice in response to increased aortic pressure. 17 Collectively, these mice deletion studies challenge the antigrowth effect of AT 2 receptor signaling. The apparently conflicting data in the neonatal cardiomyocyte model 13 and the acute infusion studies 14 may be outweighed by data from these receptor deletion studies. Furthermore, the counterregulatory hypothesis is not supported by the fact that no obvious abnormal cardiac developmental phenotype is evident in multiple mice with genetic manipulations of the AT 1 and AT 2 receptor subtypes (Table 2) .
AT 2 Receptor and Cardiac Apoptosis
An alternative antigrowth effect could be in the promotion of programmed cell death (apoptosis). There are strong links between AT 2 receptor activity and the augmentation of apoptosis in a variety of tissues, including vascular smooth muscle and endothelial cells, as well as fibroblasts, as outlined by Horiuchi et al. 2 In contrast, proapoptotic effects of AT 2 receptor signaling were not evident in two studies in cultured rat cardiomyocytes. 18, 19 In these studies, administration of angiotensin II provoked apoptosis that was inhibited by AT 1 receptor blockade but not by the AT 2 receptor blockade. Moreover, in mice with robust AT 2 receptor expression, no evidence of augmented apoptosis was suggested. 20 Hence, in the heart, the data do not support a counterregulatory role of the AT 2 receptor in mediating antigrowth effects. Perhaps the paradigm of context-specific regulation is relevant regarding the significance of AT 2 receptor signaling and apoptosis.
AT 2 Receptor and Cardiac Fibrosis
Excess AT 1 stimulation leads to left ventricular fibrosis. 21 To counterregulate this effect, AT 2 receptor activation should attenuate myocardial fibrosis. There is an antifibrotic effect of AT 2 receptor stimulation on fibroblasts extracted from cardiomyopathic hamsters. 22 This concept is supported by a study in AT 2 receptor-deficient mice exposed to aortic banding. In this study, perivascular fibrosis was attenuated in genetically ablated mice compared with wild-type control mice. 17 In a preliminary report, cardiac overexpression of AT 2 receptor in mice attenuated cardiac fibrosis but not cardiac hypertrophy. 23 In stark contrast, the AT 2 -deficient mice study by Senbonmatsu et al 16 implies that AT 2 activity is important for the left ventricular interstitial fibrotic response to pressure overload. A third view is that the cardiac AT 2 receptor stimulation has little or no influence on myocardial fibrosis 24, 25 and that fibrosis more likely is related to the prevailing blood pressure. 24 In support of this view, the degree of postinfarct myocardial fibrosis in rats was attenuated by AT 1 blockade without any significant effects of added AT 2 blockade. 26 In humans, myocardial fibrosis can be regressed by angiotensin-converting enzyme (ACE) inhibition 27 that presumably reduces stimulation of both AT 1 and AT 2 receptors. Therefore, the relationship between AT 2 receptor activity and fibrosis in the myocardium has not been definitively clarified.
Moreover, an important recent point is that AT 2 receptor stimulation can have bidirectional effects in different tissues, decreasing collagen synthesis in cultured fibroblasts but increasing synthesis in mesangial cells. 28 
From Bench to Bedside
It is now firmly established that inhibition of ACE does have a markedly beneficial effect in the treatment of heart failure. ACE inhibitor therapy, however, does not completely block angiotensin II production, and in some patients, angiotensin II levels remain elevated, in part, because of the conversion of angiotensin I to angiotensin II by chymase activity. 29 Thus, continued AT 2 receptor stimulation could occur. This hypothesis is indirectly supported by the relative upregulation of the AT 2 receptor in human heart failure, 30, 31 although this finding is controversial. 32, 33 Currently, no therapeutic agents that specifically act on the AT 2 receptor are approved for clinical trials. However, numerous AT 1 receptor blockers are available that could hypothetically shunt the activity of the cardiac RAS toward stimulation of the beneficial AT 2 receptor. Two separate clinical approaches evaluate this hypothesis. First, ACE inhibitor therapy was directly compared with AT 1 receptor antagonist therapy in a randomized controlled clinical study, ELITE II, that was adequately powered 34 in contrast to the underpowered first ELITE trial. In ELITE II, the ACE inhibitor captopril was compared with the AT 1 blocker losartan in 3152 patients aged 60 years or older, with endpoints of all-cause mortality, sudden death, or resuscitated arrest. No significant differences were found, suggesting that the beneficial effect of these two classes of agents were both via the inhibition of AT 1 receptor signaling and that beneficial AT 2 signaling played no role. Second, the addition of the AT 1 receptor blocker valsartan to preexisting therapy in the Val-HeFT study meant that the drug classes were effectively combined and compared with ACE inhibitor therapy alone. 35 The preliminary report on 5009 patients with heart failure, mostly New York Heart Association classification grade II and grade III, showed unchanged rate of mortality but reduced rate of morbidity, including hospitalization. In other experimental and human heart failure studies, the combination of an AT 1 blocker plus ACE inhibition resulted in a greater reduction in angiotensin II levels versus ACE inhibition therapy alone. 36, 37 Collectively, these data suggest that if combined RAS antagonist therapy is more successful in heart failure than individual antagonists alone, it is probably due to the combinatorial decrease in angiotensin II levels and less likely that increased stimulation of the AT 2 receptor plays a major beneficial role.
Conclusions
Angiotensin II activation promotes adverse remodeling in experimental heart failure, and these effects can be attenuated by ACE inhibition and AT 1 receptor blockade. 26,38 -40 This suggests major dependency on the AT 1 receptor, without necessarily having to invoke any specific protective role of the AT 2 receptor. 1 We do, however, believe that potential counterregulation of the proposed AT 1 -induced perivascular fibrosis by AT 2 activity 17 deserves further investigation. Furthermore, different effects of increased AT 2 activity in different tissues need to be considered. 28, 41 The overall data do not argue convincingly for a major compulsory protective role of AT 2 receptors in heart failure treated by AT 1 blockade, despite the strong evidence in specific models. 8, 26 Rather, the totality of evidence, both clinical and laboratory, is that activity of the AT 1 receptor is crucial in the progression of heart failure.
Moving from bench to bedside, there is no need to invoke the counterregulation hypothesis concerning the proposed benefits of increased AT 2 activity to explain the results of these large clinical trials in heart failure. It appears that the concept of AT 1 counterregulation by AT 2 receptor activity is too simplistic to account for all the apparently conflicting data. We acknowledge that some downstream messengers of AT 1 receptor activity unequivocally oppose those of the AT 2 receptors, for example, AT 1 -induced vasoconstriction versus kinin-mediated vasodilation. Further work is now required to understand why paths communal to both AT 1 and AT 2 signaling, such as those involving NF-B, may lead to either growth or apoptosis.
